FDA Accepts Supplement Application for ZEVTERA (Ceftobiprole Medocaril Sodium)
The FDA has accepted a supplemental application for ZEVTERA, indicating a potential expansion of its use.
Asset / Drug
Drug and asset intelligence for ZEVTERA with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.